Kornimate/medical-research-clean huggingface dataset:
epidemiological data on mast cell pathologies in france

Conditions: Mast Cell Disorder

Summary: mast cell disorders constitute a heterogeneous group of diseases, including : * mastocytosis, i.e. cutaneous, indolent and severe forms of the disease, such as aggressive mastocytosis and mast cell leukemia) ; * mast cell-associated diseases such as mast cell activation syndrome (idiopathic, secondary or clonal), affecting both children and adults. no epidemiological data are currently available in france. in france, medical care of mast cell disorders is mainly provided by a rare disease network (ceremast), whose crmr is located at the necker enfants malades hospital in paris. a total of 20 centers are located throughout france. our aim is to use this network to study patients suffering from these diseases. the overall aim of the study is to improve the understanding, diagnosis, prognosis, recognition and management of patients with mastocytosis.


Eligibility criteria:
inclusion criteria: 1. children from birth and adults of any age 2. with one of the following mast cell diseases: * mastocytoses (cutaneous, systemic and sarcomas) defined according to the who 2016 classification * mast cell activation syndromes (idiopathic, secondary and clonal) * other mast cell activation disorders (mcad-nos), defined according to the vienna classification * pre-mastocytosis or mmc (1 to 2 criteria according to who 2016 classification). 3. managed in france in a rare disease reference, constitutive or competence center (ceremast) with dgos labelization. exclusion criteria: 1. opposition of the patient or his/her parents to participation in the study.

Keywords: mast cell disease mastocytosis mast cell-associated diseases
a study to evaluate the effect of contraceptive vaginal rings on primary dysmenorrhea (p08257/mk-8175a/mk-8342b-057)

Conditions: Dysmenorrhea

Summary: the study investigates four vaginal ring groups with respect to relief of primary dysmenorrhea, and should identify at least one vaginal ring that shows clinically relevant treatment efficacy in relief of primary dysmenorrhea.

the study investigates four vaginal ring groups with respect to relief of primary dysmenorrhea, and should identify at least one vaginal ring that shows clinically relevant treatment efficacy in relief of primary dysmenorrhea. the intake of ibuprofen rescue medication and the impact on daily life is investigated: change from baseline data of these two variables will be compared between each of the four active ring groups, separately, and the placebo ring group. furthermore, the study assesses the measurement characteristics and psychometric properties of a newly developed dysmenorrhea daily dairy. vaginal bleeding pattern and general safety and tolerability will also be evaluated.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) ≥18 and ≤35 * established diagnosis of primary dysmenorrhea * if of child-bearing potential must agree to use condoms for contraception during the entire screening period, treatment period, and post-treatment period until the final study visit, unless she or her partner are surgically sterilized * agree to stop using hormonal contraceptive (combined or progestin-only), or a non hormonal intrauterine device (iud) * regular menstrual cycles ranging from 24 to 35 days in length exclusion criteria: * any of the following contraindications to the use of contraceptive steroids including: presence or a history of venous or arterial thrombotic/thromboembolic events or cerebrovascular accident (stroke, history of migraine with focal neurological symptoms, diabetes mellitus with vascular involvement, severe or multiple risk factor(s) for venous or arterial thrombosis, severe dyslipoproteinemia, severe hypertension, pancreatitis or a history thereof if associated with severe hypertriglyceridaemia, presence or history of severe hepatic (liver) disease, including benign or malignant tumors, known or suspected sex steroid-influenced malignancies, and/or undiagnosed vaginal bleeding * pregnant or breastfeeding * secondary dysmenorrhea * has not had spontaneous menstruation following a delivery or abortion * participated in an investigational drug study within 30 days * history of malignancy ≤5 years * documented abnormal cervical smear result within 6 months * use of recreational or illicit drugs * consumes \>2 alcoholic drinks per day or \>14 alcoholic drinks per week, or engages in binge drinking * allergy/sensitivity to ibuprofen, or any contraindication to its use, or has experienced asthma, urticaria, or allergic-type reactions after taking aspirin, or other nonsteroidal anti inflammatory drugs * has been sterilized using a fallopian tube occlusion device * is receiving, or has received sex hormones for any purpose other than contraception within 2 months or injectable hormonal contraception within 6 months
prognosis of paroxysmal kinesigenic choreoathetosis in korea

Conditions: Paroxysmal Kinesigenic Choreoathetosis

Summary: the aim of this study is to assess the prognosis of paroxysmal kinesigenic choreoathetosis (pkc) in korean.

pkc is a hyperkinetic movement disorder including dystonia, chorea, athetosis, or ballism, which are characteristically triggered by a sudden movement from rest. the prevalence of this disorder is estimated to be 1 in 150,000 population. males are more commonly affected than females, and the age of onset is typically in childhood or adolescence. pkc is mainly a familial disorder with autosomal dominant inheritance and incomplete penetrance, but it can occur sporadically. the prrt2 (proline-rich transmembrane protein 2) gene is believed to be the major causative gene. the prognosis of pkc is usually favorable. the severity and frequency of the attacks are reduced by anticonvulsant medication such as carbamazepine, and the number of the attacks decreases at the age of 20-30 years. however, there has been little study of long-term prognosis of pkc, and no study has been conducted in korean population.

Eligibility criteria:
inclusion criteria: * male or female pkc patients who were18 years of age and older * subjects were diagnosed as paroxysmal kinesigenic choreoathetosis (pkc) * subjects were enrolled voluntarily and understood the contents of this trial exclusion criteria: * existence of lesions on the brain * existence of neurological deficit that suspected lesions on the brain * existence of epileptiform discharges on electroencephalogram * subjects with secondary pkc which was caused by other disorder or illness * existence of illness or problems which made difficult to be enrolled to this trial judged by clinicians

Keywords: paroxysmal kinesigenic choreoathetosis prognosis korean population
epinephrine in the pediatric intensive care unit: a dose-effect trial

Conditions: Hypotension

Summary: the use of peri-arrest bolus epinephrine (pbe) has emerged as a rescue strategy for life-threatening hypotension in pediatric intensive care units (icu) despite scant published data supporting its use in this setting. as optimal dosing of pbe in this population is unclear, we aim to determine if an initial dose of 0.5 mcg/kg versus 1.0 mcg/kg yields differences in hemodynamic outcomes. the epi dose study is a single-center, prospective, randomized, double-blind, dose-effect trial measuring systolic blood pressure (sbp) before and after pbe is given. we hypothesize that the 1.0 mcg/kg group will have more robust increases in sbp.

in order to test the hypothesis that pbe doses of 1.0 mcg/kg will have more robust increases in sbp as compared to 0.5 mcg/kg in critically ill children and young adults with acute hypotension, we plan to conduct a phase ii, single-center, prospective, randomized, double-blind, dose-effect trial. children and young adults \<26 years of age who, at the discretion of the clinical team, require rescue pbe for life-threatening hypotension and meet inclusion/exclusion criteria will be enrolled. prior to randomization, our pharmacy team will prepare treatment packets with 3 pre-mixed pbe which will be stocked in the icus with either 5 mcg/ml or 10 mcg/ml of epinephrine. clinicians will be instructed to use 0.1 ml/kg of the experimental syringe for the initial dose, resulting in target doses of 0.5 mcg/kg (arm 1) or 1 mcg/kg (arm 2), respectively. treatment packs will be labeled according to the randomization scheme, and only the pharmacy team will have knowledge of the concentration of epinephrine in each package. nurses will be instructed to record the exact time of the experimental dose, around which all time-sensitive data will be collected. the clinicians, patients and research team will be blinded to the intervention. we will not restrict any other interventions chosen by the clinical team. unblinded interim analyses will be performed after the first 6 months of enrollment, and every 12 months thereafter through study completion and reported to the data and safety monitoring board (dsmb).

Eligibility criteria:
inclusion criteria: 1. male or female less than 26 years of age. 2. admitted to bch and receiving care in a participating icu. 3. is prescribed bde for acute hypotension deemed to be life-threatening in the judgement of the treating clinician. exclusion criteria: 1. has opted out of the study prior to enrollment. 2. has orders in place which limit resuscitation efforts. 3. is actively receiving chest compressions while pbe is administered. 4. is receiving care in the neonatal intensive care unit. 5. is receiving care outside of the icu at the time pbe is administered (i.e procedural areas). 6. is pregnant or breastfeeding. 7. is a prisoner. 8. is a ward if the state (dcf custody).
nasoneb delivery of an intranasal steroid

Conditions: Perennial Allergic Rhinitis

Summary: the purpose of this study is to see if a nasal steroid drug delivered to the nose with the nasoneb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).


Eligibility criteria:
inclusion criteria 1. males and females between 18 and 55 years of age. 2. history of perennial allergic rhinitis. 3. positive skin test to dust mite, dog, cat or indoor mold antigen. 4. and a combined nasal am and pm score of ≥4 for nasal congestion in the day preceding entry and total nasal symptom score greater than 8. exclusion criteria 1. physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease. 2. pregnant or lactating women. 3. subjects treated with systemic steroids during the previous 30 days. 4. subjects treated with topical (inhaled, intranasal or intraocular) steroids, nasalcrom or opticrom during the previous 30 days. 5. subjects treated with oral antihistamine/decongestants during the previous seven days. 6. subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days. 7. subjects treated with immunotherapy and are escalating their dose. 8. subjects on chronic anti-asthma medications. 9. subjects with polyps in the nose or a significantly displaced septum. 10. upper respiratory infection within 14 days prior to study start.

Keywords: allergy
patient attributes for optimal treatment outcome in irritable bowel syndrome.

Conditions: Irritable Bowel Syndrome

Summary: the purpose of this study is to determine if any specific patient characteristics lead to improved outcome of ibs treatment, when conventional treatment as well as cognitive behavioral therapy is used in combination.

although research has demonstrated the efficacy of various psychological and pharmacological treatments for irritable bowel syndrome (ibs)1, health professionals have limited information about how to determine which specific treatment regimens lead to optimal outcomes for specific ibs populations 2,3. a prevalent syndrome, with high healthcare costs, ibs is a debilitating chronic functional bowel disorder with increasingly interconnected psychosocial and gastrointestinal afflictions4. in general, ibs sufferers have not been found to respond consistently to a single medication or class of medications5. in the wake of the failures of medical therapies, many psychological interventions, adjunct to standard ibs treatments, have been examined1,6 such as blanchard and scharff's 2002 review of 12 random controlled trials that found strong evidence for the utility of hypnotherapy, cognitive behavioral therapy (cbt), and brief psychodynamic psychotherapy in helping to alleviate ibs symptoms7. similarly, in a more recent study involving a meta-analysis of seventeen studies, with randomized trials comparing classes of psychological interventions, found that these psychological treatments also play a role in improving quality of life of ibs suffers1. among these psychological interventions, cognitive behavioral therapy (cbt), a prescriptive therapy that specifically targets faulty thinking patterns, has been found to be quite effective in many empirical investigations. recent evaluations of cbt interventions have found the therapy to have a direct effect on global improvements of ibs symptoms and quality of life8. despite its demonstrated effectiveness, however, cbt does not work for all patients3,6,8. the successes of medical therapy alone compared to a treatment regimen combining psychological and pharmaceutical interventions have been greeted with mixed results- leading to the unnecessary waste of health resources in the course of treatment3,6. to decrease medical costs, as well to foster optimal treatment for ibs patients, there is a need for a better method of identifying which patients will most benefit from specific treatment options s (i.e. conventional medical treatment versus standard treatment and cbt)2,3.

Eligibility criteria:
inclusion criteria: * all newly diagnosed ibs patients using rome iii criteria above the age of 18. exclusion criteria: * patients with non-functional gi disorders, severe psychiatric disorders, including psychotic disorders, actively suicidal or alcoholism/other drug dependencies. * pregnant women and minors(under age 18) will also be excluded. * prisoners will also be excluded.

Keywords: irritable bowel syndrome
impact of automatic polyp detection system on adenoma detection rate

Conditions: Colonic Polyps; Colorectal Adenomas

Summary: in recent years, with the continuous development of artificial intelligence, automatic polyp detection systems have shown its potential in increasing the colorectal lesions. yet, whether this system can increase polyp and adenoma detection rates in the real clinical setting is still need to be proved. the primary objective of this study is to examine whether a combination of colonoscopy and a deep learning-based automatic polyp detection system is a feasible way to increase adenoma detection rate compared to standard colonoscopy.


Eligibility criteria:
inclusion criteria: * patients aged between 40-85 years old who have indications for screening, surveillance and diagnostic. * patients who have signed inform consent form. exclusion criteria: * patients who have undergone colonic resection * patients with intracranial and/or central nervous system disease, including cerebral infarction and cerebral hemorrhage. * patients with severe chronic cardiopulmonary and renal disease. * patients who are unwilling or unable to consent. * patients who are not suitable for colonoscopy * patients who received urgent or therapeutic colonoscopy * patients with pregnancy, inflammatory bowel disease, polyposis of colon, colorectal cancer, or intestinal obstruction * patients who are taking aspirin, clopidogrel or other anticoagulants * patients with withdrawal time \< 6 min
c-brace ii spinal cord injury

Conditions: Spinal Cord Injury

Summary: a randomized, repeated measures comparative design study to compare use of a micro-processor controlled knee-ankle-foot orthosis vs. traditional care knee-ankle-foot-orthosis (kafo) models following discharge from inpatient rehabilitation.


Eligibility criteria:
all participants: inclusion criteria: * be within 3-24 months post spinal cord injury diagnosis * 18-80 years * must be able to demonstrate the ability to charge assigned sensors during 3-month home trial period on and off and sufficient memory ability to wear the devices each day during use of the orthoses. exclusion criteria: * unstable neurological, cardiovascular, or cancer diagnoses. * cognitive impairments that limit study participation in addition to the above inclusion criteria, the following criteria must be met to be designated into the study interventional tract (c-brace ii): inclusion criteria: * requires orthotic bracing for lower extremity instability, including the knee joint, unilaterally or bilaterally exclusion criteria: * body weight over 275 lbs * flexion contracture in the knee and/or hip joint in excess of 10 degrees * non-correctable knee varus/valgus in excess of 10 degrees * moderate to severe spasticity * leg length discrepancy in excess of 6" (15.24 cm) * inability to stabilize the trunk with or without assistive devices (crutches, cane, etc.) * inability to successfully use c-brace trial tool in advancement of leg/s.

Keywords: orthotic c-brace
efficacy and safety of 0.25% desoximetasone cream (topoxy®) in the treatment of scalp psoriasis

Conditions: Scalp Psoriasis

Summary: the purpose of this study is to evaluate efficacy and safety of 0.25% desoximetasone cream (topoxy®) compare with 0.25% desoximetasone cream (topicorte®) in the treatment of scalp psoriasis.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. diagnosed with scalp psoriasis by dermatologist 3. has scalp psoriasis involve ≥ 10% of total scalp area and also has clinical signs, or a previous diagnosis, of psoriasis on the trunk and/or limbs 4. total severity of scalp psoriasis should be graded in mild to very severe according to investigator's global assessment score (iga) 5. clinical signs (redness, thickness, scaliness) should be scored as "moderate" for at least 1 sign and "slight" on each of the other two signs 6. all participants agree to participate in the study and already complete and sign consent form exclusion criteria: 1. treated with these medications before including in the study * topical corticosteroid for scalp psoriasis (except emollients and shampoo) within 2 weeks * very potent topical corticosteroids for psoriasis on other area or narrow band ultraviolet b (nb-uvb) within 2 weeks * oral psoralen plus ultraviolet a (puva) or oral medication (methotrexate, acitretin, cyclosporine) within 4 weeks * biologic agents or concomitant medication that could affect scalp psoriasis (beta- blockers, antimalarial drugs, lithium ) within 6 months 2. has skin infection or atrophic skin on the scalp 3. has history of allergic reaction or hypersensitivity to 0.25% desoximetasone 4. female participants with pregnancy or in lactation period 5. participants who unable to come for follow-up visits at hospital 6. participants with other underlying disease e.g. diabetes mellitus, hypertension, thyroid disease 7. vulnerable subject e.g. illiterate person

Keywords: scalp psoriasis 0.25% desoximetasone cream
the improving care in chronic obstructive lung disease study a cluster randomized trial

Conditions: COPD

Summary: background the swiss health ministry launched a national quality program "qualiccare" in 2011 to improve healthcare for patients with copd. the aim of this study is to determine whether participation in the copd quality initiative ("qualiccare") improves adherence to recommended clinical processes and shows impact on patients copd care and on quality of life in patients with copd.

the care in obstructive lung disease study (carol) is a cluster-randomized controlled trial with randomization on the practice level. thirty practices will be randomly assigned to equally sized intervention group or control group. each general practioner (gp) of a practice will approach consecutively and regardless the reason for the current encounter, copd patients diagnosed by spirometric evaluation (fev1/ fvc \< 0.70), aged 45 years older, with a smoking history of = 10 pack-years (py). gps in the intervention group will receive "qualiccare" education, which addresses knowledge, decision-making and behavioural aspects as well as delivery of care according to copd quality indicators and evidence based key elements. in the control group no educational intervention will be applied and copd patients will be treated as usual. the study period is one year. the primary outcome measure is an aggregated score of relevant clinical processes defining elements in the care of patients with copd: smoking cessation counseling, influenza vaccination, motivation for physical activity, appropriate pharmacotherapy, patient education and collaborative care.

Eligibility criteria:
inclusion criteria: * males and females = 45yrs of age and * smoker or ex-smoker (with at least 10 py) and * obstruction in spirometry fev1/fvc\< 0.7 exclusion criteria: * no obstruction in spirometry (fev1/fvc \> 0.7) or * patients with history of asthma or hay fever or * other concomitant pulmonary disease or * patients with malignancies of any other system and/or other severe disease with an estimated life expectancy of less than six months or * insufficient german language skills or * patients who contact the practice for emergencies only or as a substitute practice
thyromental height test (tmht) as a predictor of difficult airway in obese patients

Conditions: Difficult Airway Intubation

Summary: difficult airway management is a major concern for anesthetists and contributes to perioperative morbidity and mortality. the incidence of difficult intubation in the obese population with a bmi of greater than 30 has been reported to be 15.8%. thyromental height test (tmht) is a new bedside test for difficult airway, it is a measure of the height between the anterior borders of the mentum and thyroid cartilage. tmht can act as a surrogate for amount of mandibular protrusion; dimensions of submandibular space; and anterior position of the larynx. it appears promising as a single anatomical measure to predict the risk of difficult laryngoscopy.


Eligibility criteria:
inclusion criteria: * patients aged between 18-60 years old, asa physical status ii\& iii with bmi \> 30 kg/m2 who will undergo elective surgical procedures under general anesthesia using endotracheal intubation with conventional laryngoscopy exclusion criteria: * patients with neuromuscular disorders, craniofacial abnormalities, abnormal dentition, uncooperative, who need awake intubation and patients who undergoing emergency operations will be excluded
the effect of health provider's feedback on physical activity surveillance using wearable device-smartphone application for resolution of metabolic syndrome

Conditions: Metabolic Syndrome; Physical Activity

Summary: the effect of health provider's feedback on physical activity surveillance using wearable device-smartphone application for resolution of metabolic syndrome; a 12-week randomized control study

patients diagnosed with metabolic syndrome were recruited and prescribed to live for 12 weeks using a wrist-wearable device (b.band, b life inc, korea). the block randomization method was used to distribute the participants between an intervention group (n=35) and control group (n=32). in the intervention group, an experienced study coordinator provided feedback on physical activity to individuals through telephone counseling every other week.

Eligibility criteria:
inclusion criteria: * smart phone user exclusion criteria: -